BeiGene | A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Beigene Study ID

BGB-A317-302

ClinicalTrials.gov ID

NCT03430843

EudraCT Number

2017-003699-30

China Drug Trials ID

CTR20171026

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

Study Protocol Statistical Analysis Plan Plain Language Summary

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

Study Protocol Statistical Analysis Plan Plain Language Summary